TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02367989

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0g barley β-glucan with fibre
Description: Food containing no barley β-glucan, but matches fibre content in β-glucan treatments
Study: NCT04213846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Mobile Alcohol Expectancy Intervention
Description: Participants randomized to the intervention condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
Study: NCT04622462

Intervention type: PROCEDURE
Intervention: Standard of Care Histopathology
Description: Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer

Intervention type: PROCEDURE
Intervention: STRATICYTE Assessment
Description: Assessment for risk of progression to oral cancer
Study: NCT03516149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling Exercise
Description: Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets
Study: NCT01939860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written and verbal patient education on hypertension and its treatment
Study: NCT05516342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAD IT! Programming
Description: LEAD IT! is an intervention that enables persons with dementia to lead activities for their peers. The activities take place on tablets.
Study: NCT03248570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
Study: NCT01376544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol designed to evaluate (SLE 5000 ventilator)
Description: Assist control ventilation and pressure support ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol designed to evaluate (SLE 5000 ventilator)
Description: Assist control ventilation and pressure support ventilation
Study: NCT02443285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Cefotaxime 2 gram every12 hours for 5 days
Study: NCT03248570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
Study: NCT00347659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLVR System
Description: Treatment is administered in a single treatment session.
Study: NCT01965080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: One tablet Exemestane 25 mg daily
Study: NCT03037060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]-(+)-PHNO PET scan
Description: PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Self-Administration
Description: Session for assessing motivation for consuming alcohol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craving Task
Description: Cue exposure paradigm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan scan to analyze the PET data will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Assessment
Description: Cognitive questionnaires administered over course of study.
Study: NCT00354393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine ditartrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Study: NCT04941417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Two to three cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor will be administered before surgery, followed by another one to two cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor and PD-(L)1 inhibitor monotherapy for up to 1 year.
Study: NCT03871933

Intervention type: OTHER
Intervention: Measurement of lung function, electrocardiography, echocardiography and autonomic function
Description: Measurement of lung function, electrocardiography, echocardiography and autonomic function

Intervention type: OTHER
Intervention: Measurement of lung function, electrocardiography, echocardiography and autonomic function
Description: Measurement of lung function, electrocardiography, echocardiography and autonomic function
Study: NCT03514368

Intervention type: OTHER
Group type: OTHER
Intervention: Patients treated with immune checkpoint blockade
Description: Tumor biopsy specimens and blood samples will be collected at different time points:~* Baseline~* before the 3rd ICB administration (blood samples only)~* before the 5th ICB administration (blood samples only)~* at the time of treatment permanent discontinuation (blood samples only)~* at the time of progression (tumor biopsy specimens only)~* after the last dose of ICB treatment (blood samples only taken twice per year until study termination)
Study: NCT01796665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acanya Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product
Study: NCT02342912

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Media Treatments
Description: Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
Study: NCT04492722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10 mg
Description: Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.
Study: NCT02443285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: Ceftriaxone 2 gm every 24 hours for 5 days
Study: NCT02026362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT:Multiple Antigens Specific Cellular Therapy
Description: autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

Intervention type: OTHER
Group type: OTHER
Intervention: The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
Study: NCT04437277

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hepatitis C, serology
Description: Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
Study: NCT01681862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Health Record
Description: Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan.
Study: NCT03045627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AraC
Description: ARA-C subcutaneously in a 12-hour infusion on days 1 through 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AraC
Description: ARA-C subcutaneously in a 12-hour infusion on days 1 through 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclarubicin
Description: Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclarubicin
Description: Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-G-CSF
Description: PEG-G-CSF 6mg subcutaneously on days 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
Study: NCT05636891

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimus
Description: * NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stimus
Description: * NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)
Study: NCT05578469

Intervention type: PROCEDURE
Intervention: surgical treatment of Marfan Syndrome with subluxation lens
Description: different surgical treatment of Marfan Syndrome with subluxation lens

Intervention type: PROCEDURE
Intervention: surgical treatment of Marfan Syndrome with subluxation lens
Description: different surgical treatment of Marfan Syndrome with subluxation lens
Study: NCT02999698

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT03562845

Intervention type: OTHER
Intervention: NA-Observational only
Description: NA-Observational only

Intervention type: OTHER
Intervention: NA-Observational only
Description: NA-Observational only
Study: NCT05476133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Executive functions training-elementary and Promoting executive function in in the classroom
Description: evidence based practice that target executive function skills in early elementary years.
Study: NCT00850447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Videogame
Description: Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
Study: NCT02002858

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational-Support Psychotherapy
Description: Educational-based psychotherapy and standard smoking cessation treatment program
Study: NCT04659668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MMG-23-04-2019
Description: The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot.
Study: NCT04224948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET MRI scan
Description: Standard of care includes a baseline PET-CT and conventional CT after 2 cycles of neoadjuvant chemotherapy, and after 5-6 cycles, of neoadjuvant chemotherapy, as per current practice/ standard of care.~Patients that enroll in the trial will receive two additional PET MRI scans- one at baseline and one after 1 cycle of chemotherapy
Study: NCT03316157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProSure
Description: Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
Study: NCT03999073

Intervention type: OTHER
Intervention: Ultrasound measurement
Description: Ultrasound measurement

Intervention type: OTHER
Intervention: Ultrasound measurement
Description: Ultrasound measurement
Study: NCT02389738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis catheter
Description: Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
Study: NCT03163329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAVR
Description: Surgical Aortic Valve Replacement
Study: NCT03563560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib
Description: ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib
Description: ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
Study: NCT02342912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Treatments
Description: Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Treatments
Description: Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
Study: NCT03563560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
Study: NCT01620827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Landline Phone Calls
Description: Follow-up phone calls are made from the hospital landline phones in a research office
Study: NCT04427111

Intervention type: DEVICE
Intervention: Non-titratable-customized mandibular advancement device
Description: The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.